Skip to main content

Table 4 Cox regression analysis on new-onset type2 DM according to years of exposure

From: Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study

(N)

Unadjusted Hazard Ratioa

Adjusted Hazard Ratioa

HR

95% CI

p-value

HR

95% CI

HR

Non-statin (5273)

1.000

  

1.000

  

Atorvastatin (1071)

1.791

1.598

2.009

<  0.0001

1.942

1.661

2.269

1.942

 < 2 years (137)

1.027

0.846

1.248

0.7853

0.989

0.8

1.222

0.989

 2–5 years (127)

1.007

0.822

1.234

0.9448

1.005

0.791

1.277

1.005

 ≥ 5 years (807)

1.907

1.563

2.327

<  0.0001

1.83

1.487

2.252

1.83

Lovastatin (771)

1.847

1.624

2.101

<  0.0001

1.915

1.621

2.263

1.915

 < 2 years (103)

1.07

0.862

1.328

0.5382

1.005

0.793

1.275

1.005

 2–5 years (92)

1.113

0.885

1.401

0.3599

1.068

0.826

1.382

1.068

 ≥ 5 years (576)

1.942

1.551

2.431

<  0.0001

1.846

1.458

2.337

<  0.0.0001

Pravastatin (391)

1.662

1.39

1.986

<  0.0001

1.758

1.429

2.164

<  0.0001

 < 2 years (42)

0.914

0.677

1.234

0.5582

0.981

0.706

1.363

0.9093

 2–5 years (50)

1.256

0.946

1.666

0.1148

1.236

0.899

1.699

0.1911

 ≥ 5 years (299)

1.779

1.335

2.371

<  0.0001

1.633

1.211

2.203

0.0013

Rosuvastatin (243)

1.723

1.381

2.15

<  0.0001

1.932

1.511

2.471

< 0.0001

 < 2 years (32)

0.931

0.653

1.328

0.6927

0.826

0.547

1.247

0.3635

 2–5 years (30)

1.727

1.198

2.491

0.0034

1.712

1.133

2.586

0.0107

 ≥ 5 years (181)

1.578

1.053

2.365

0.0271

1.587

1.051

2.398

0.0282

Simvastatin (2711)

1.669

1.531

1.819

<  0.0001

1.794

1.567

2.055

< 0.0001

 < 2 years (310)

0.93

0.802

1.078

0.3341

0.912

0.776

1.071

0.2617

 2–5 years (290)

0.988

0.846

1.155

0.8804

0.979

0.824

1.163

0.8103

 ≥ 5 years (2111)

1.967

1.701

2.274

<  0.0001

1.916

1.647

2.228

< 0.0001

  1. aModel was adjusted for age, sex, income level, urbanization of residence, Charlson comorbidity index, comorbidities (hypertension, prediabetes, liver disease, renal disease, metabolic disorder, family history of diabetes, obesity, hypothyroidism), number of outpatient visits in the previous 3 years, number of hospitalizations in the previous 3 years, comedications (fibrates, niacin, corticosteroids, hypertension medications). *p < 0.001. HR, hazard ratio; CI, confidence interval